The potential for long-term toxicity is a critical consideration, particularly for therapeutic cancer vaccines. Some concerns include the possibility of chronic inflammation or autoimmune diseases resulting from prolonged immune activation. Long-term studies and vigilant post-marketing surveillance are essential to identify and mitigate any such risks over time.
